Clinithink secures investment to scale AI tech, expand into Asia-Pac

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Milkos)
(Image: Getty/Milkos)

Related tags: Clinithink, Artificial intelligence, AI, NLP, Clinical trials, Patient recruitment

Clinithink has secured investors to scale its technology, which leverages unstructured data to guide treatment decisions, identify clinical trial participants, and ensure proper reimbursement.

Clinithink has received a growth-equity investment from TT Capital Partners (TTCP) and the MSD Global Health Innovation Fund (GHI) to scale its patented CLiX natural language processing (NLP) platform.

According to the company, its technology uses artificial intelligence (AI) to “read” and interpret up to two million clinical documents an hour.

Clinithink CEO Chris Tackaberry said the funding will be used to broaden the company’s product and service offering. The company also plans to use the investment to “contribute to the acceleration of our growth in the US and the UK, and to expand into Asia Pacific.”

Tackaberry told us Clinithink explored a number of options as it pertains to investors, as the company had “considerable interest”​ in its offering. “However, we feel that, although they are very different, the partners we have chosen really complement our strategic vision,” ​he added.

A growing market – and a Guinness World Record

The demand for Clinithink’s offering has evolved as the market better understands “the power and value of real-world data,”​ said Sarah Beeby, executive vice president, general manager, life sciences, Clinithink.

“We are in a growing market, and our unique combination of pioneering AI approaches with real-world data has driven a rapid expansion in the way our partners and customers see the value we can create,”​ she told us.

“This has meant that they are looking to utilize our offering in a far broader range of use-cases across the health care and life sciences ecosystems,”​ Beeby added.

As part of a collaboration, the company recently set a Guinness World Record for the fastest genetic diagnosis​ – at a time of approximately 19.5 hours.

Clinithink’s technology also supports patient matching for clinical trials and real-world evidence (RWE) studies. Additionally, it can be used to aid site selection and protocol optimization, and provides revenue cycle management capabilities to help hospitals and health systems, according to the company.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars